scispace - formally typeset
K

Karine Breckpot

Researcher at Vrije Universiteit Brussel

Publications -  162
Citations -  8325

Karine Breckpot is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Immunotherapy & Immune system. The author has an hindex of 49, co-authored 141 publications receiving 6687 citations. Previous affiliations of Karine Breckpot include Free University of Brussels & VU University Amsterdam.

Papers
More filters
Journal ArticleDOI

Consensus guidelines for the detection of immunogenic cell death

Oliver Kepp, +81 more
- 29 Oct 2014 - 
TL;DR: Strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative I CD inducers are outlined, based on a high-content, high-throughput platform that was recently developed.
Journal ArticleDOI

Combinatorial Strategies for the Induction of Immunogenic Cell Death

TL;DR: This work discusses current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD, and suggests that novel therapeutic regimens that trigger ICD are urgently awaited.
Journal ArticleDOI

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Abhishek D. Garg, +53 more
TL;DR: The main molecular, immunological, preclinical, and clinical aspects of ICD are summarized and tabulate in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.
Journal ArticleDOI

Lentiviral vectors in gene therapy: their current status and future potential.

TL;DR: The intention of this review is to describe the main scientific steps leading to the engineering of HIV-1 lentiviral vectors and place them in the context of current human gene therapy.
Journal ArticleDOI

Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages

TL;DR: These findings provide preclinical proof of concept that anti-MMR nanobodies can be used to selectively target and image TAM subpopulations in vivo, and target pro-angiogenic MMR+ TAMs.